Loading...
ROCO
4174
Market cap205mUSD
Nov 13, Last price  
24.45TWD
Name

OBI Pharma Inc

Chart & Performance

D1W1MN
ROCO:4174 chart
P/E
—
P/S
102.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.81%
Rev. gr., 5y
135.14%
Revenues
63m
+50.85%
0000092,422,000376,00013,339,000872,000140,886,00018,772,0004,711,00041,549,00062,678,000
Net income
-2.31b
L+120.74%
-127,587,000-255,275,000-438,584,000-667,007,000-941,337,000-1,110,128,000-1,379,436,000-1,222,242,000-1,439,590,000-1,489,897,000-1,717,890,000-1,899,324,000-1,046,474,999-2,310,026,000
CFO
-1.83b
L+10.92%
-508,224,000-117,635,000-104,156,000-464,217,000-372,204,000-840,096,000-1,106,891,000-864,309,000-1,046,855,000-1,609,441,000-1,064,479,000-1,619,702,000-1,652,980,000-1,833,513,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
URL
https://www.obipharma.com/
IPO date
Dec 12, 2012
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT